The Indian Pharmaceutical Alliance (IPA) represents 23 national research-based companies. Collectively, IPA member companies account for over 85% of the private sector investment in pharmaceutical research and development. They contribute over 80% of pharmaceutical exports and serve over 60% of the domestic market. This makes IPA a key voice in shaping the future of both Indian and global healthcare.
The Access–Affordability Equation
The Indian Pharmaceutical Alliance (IPA) has been at the forefront of advocating for a pricing and regulatory framework that ensures quality medicines remain accessible to all, while still enabling the industry to invest in next-generation research and therapies. A critical step in this journey is the modernization of Schedule M, India’s core standard for Good Manufacturing Practices (GMP). Now being upgraded to meet WHO-GMP benchmarks, this reform aims to raise quality standards across the industry.
Equitable Innovation Through Patent Policy
Founded in 1999 under the leadership of Dilip G Shah (1941–2019), an industry veteran and alumnus of IIM Ahmedabad, IPA was established to represent the Indian pharmaceutical industry’s issues that advocate for a balanced and inclusive intellectual property framework.
When the Indian Patents Act of 1970 was amended in 2005, It played a pivotal role in safeguarding access to medicines by influencing the wording of Section 3(d) clause to prevent patent ever-greening, ensuring that patents promoted innovations but did not extend monopolies by making trivial changes to existing innovations.
For 25 years, IPA has championed rational drug pricing, quality manufacturing, and a strong innovation ecosystem — working closely with policymakers, regulators, and global partners to make India a trusted pharmaceutical hub.
Mr. Samir Mehta
President, IPA
Chairman, Torrent Pharmaceuticals
IPA’s mission is clear — by 2047, India must not only be the pharmacy of the world, but also the cradle of next-gen innovation. Together, we aim to discover 100 new medicines in India’s 100th year of independence.
Dr. Sharvil Patel
Vice President, IPA
Managing Director, Zydus Lifesciences
IPA drives strategic conversations on policy, pricing, trade, quality, and innovation — with one goal: equitable access to affordable medicines. By 2047, India’s pharma industry is poised to reach $450–500 billion, placing it at the heart of global healthcare.
Mr. Sudarshan Jain
Secretary General
Indian Pharmaceutical Alliance
IPA and the COVID Response
World’s Largest Vaccination Drive
India administered over 2.2 billion COVID-19 vaccine doses, demonstrating unmatched scale and coordination.
24/7 Manufacturing Continuity
IPA member companies kept essential production running through lockdowns, leveraging domestic resilience and indigenous supply chains.
Global Pharmacy in Action
India supplied vital COVID-19 medicines and vaccines to 150+ countries, reinforcing its position as the Pharmacy of the World.
Regulatory Agility
Rapid coordination with authorities enabled emergency approvals and access to critical drugs, PPE, and diagnostics — without compromising safety.
World’s Largest Vaccination Drive
India administered over 2.2 billion COVID-19 vaccine doses, demonstrating unmatched scale and coordination.
24/7 Manufacturing Continuity
IPA member companies kept essential production running through lockdowns, leveraging domestic resilience and indigenous supply chains.
Global Pharmacy in Action
India supplied vital COVID-19 medicines and vaccines to 150+ countries, reinforcing its position as the Pharmacy of the World.
Regulatory Agility
Rapid coordination with authorities enabled emergency approvals and access to critical drugs, PPE, and diagnostics — without compromising safety.
Public–Private Collaboration
IPA companies partnered with the government, scientists, and logistics networks to scale oxygen production, strengthen supply chains, and support healthcare infrastructure.